Research desk · ADXN · Nasdaq
ADXN Stock
SEC financials, peer compare, and chart. Scores open the matching desk. Research only — not advice.
Addex Therapeutics Ltd · Pharmaceutical Preparations
Addex Therapeutics Ltd financial statements, chart, and peer compare from SEC filings.
Addex Therapeutics Ltd (ADXN) discovers, develops, or markets pharmaceutical products.
- Market cap
- $519.57M
- P/E
- —
- Op. margin
- -681.82%
- Profit margin
- 1,746.04%
- FCF margin
- -1,330.07%
- ROE
- 72.91%
Related Health Care stocks: ANIX stock financials · SMMT stock financials · PVLA stock financials · RLAY stock financials · ROIV stock financials
ADXN financial statements
Each Compare name is its own block of years. Filing lines are SEC reports; P/E and price sit on that name’s TTM column only.
ADXN stock peer compare
Each bar is that name’s percent vs its last TTM, on one zero line. Zero is unchanged. This ticker is the black bar.
Focus chart
Zero is unchanged vs last TTM. Every name is a percent for the metric you pick.
ADXN stock peer headlines
Yahoo Finance RSS for ADXN and the names in Compare.
| Ticker | Date | Headline |
|---|---|---|
| Loading headlines… | ||
ADXN stock price chart
Overlays follow the Compare table.
ADXN stock — research snapshot
Screen strengths and watchouts for ADXN stock from the latest Misprise snapshot.
Strengths
- ROA 66.1% — strong returns on assets.
- ROE 72.9% — efficient equity returns.
- Profit margin 1,746.0% — durable bottom-line quality.
- Debt/equity 0.00 — leverage looks manageable.
- Current ratio 4.42 — liquidity cushion.
Watchouts
- Operating margin -681.8% — thin operating cushion.
- Negative FCF margin — cash generation is under pressure.
- Revenue CAGR negative — multi-year top-line contraction.
- Recent revenue growth -75.0% — near-term top-line pressure.
- Rev CAGR 5Y -31.9%
- Rev CAGR 3Y -48.3%
- EPS CAGR 5Y —
- EPS CAGR 3Y —
- FCF CAGR 5Y -10.8%
- FCF CAGR 3Y -28.6%
ADXN stock FAQs
Short answers for ADXN stock — statements, sector, and how this page is meant to be used.
What is ADXN stock?
Addex Therapeutics Ltd (ADXN) discovers, develops, or markets pharmaceutical products. ADXN stock sits in Health Care (Pharmaceutical Preparations), listed on Nasdaq.
Where can I find Addex Therapeutics Ltd financial statements?
Addex Therapeutics Ltd financial statements — income statement, balance sheet, and cash flow — are on this ADXN stock page, parsed from SEC 10-K and 10-Q filings. Use Annual or Quarterly, then the statement tabs. Research only.
What happened to ADXN stock?
This page is a research snapshot of Addex Therapeutics Ltd (ADXN) from the latest SEC filings in the Misprise database as of FY2024. It is not a news feed or a delisting notice. Open the financial statements, chart, and peer compare below, then read the filings. Research only — not financial advice.
Does this page show the ADXN stock price?
The live chart on this ADXN stock page is the same TradingView chart as the screener. Statement tables use SEC filings. Any price or multiple on the TTM column is a market snapshot from the last seed, not a real-time quote. Research only.
What sector is ADXN stock in?
Addex Therapeutics Ltd is classified in Pharmaceutical Preparations, inside the Health Care sector, and trades on Nasdaq. This page is a research snapshot, not a full company profile.
How do I read ADXN financial statements?
Start with this ticker’s block (TTM, then its fiscal years or quarters). Each Compare name is a separate block of its own periods — not mixed by year. A blank is a period we do not have, not a zero. Research only — not a buy or sell.
Where does the ADXN statement data come from?
Income, balance sheet, and cash-flow lines are parsed from SEC company filings (10-K / 10-Q and 20-F). TTM is the last four reported quarters added together, not a separate filing. P/E, forward P/E, price, and market cap are a market quote at last seed — trailing P/E from the quote when available, otherwise last price divided by TTM EPS. They are not 10-K line items and appear on the TTM column only. Research only — not financial advice.
Where can I find the ADXN income statement, balance sheet, and cash flow?
On this ADXN stock page, open Financial statements and use the Income, Balance sheet, and Cash flow tabs. Growth and valuation sit under More. Filing figures are from SEC reports; valuation multiples are the market snapshot described above.
What is the Misprise Score for ADXN stock?
ADXN stock currently scores 16/100 (Watch / incomplete (<60)). Addex Therapeutics Ltd scores weaker or incomplete on durable growth/quality inputs — leverage, coverage, and recent results deserve extra scrutiny. The score is a screen of quality, growth, and balance-sheet inputs — not a price target. Compare it in the Misprise screener; it is not a separate score page.
How is the ADXN comparison winner decided?
Lead and Tie follow the number printed on each factor row, not a blended category score. Growth, quality, score, current ratio, and coverage: the higher figure leads. Value multiples (P/E, PEG, P/B, P/S) and debt ratios: the lower figure leads. Tie appears only when those printed numbers match. The header winner is whoever takes more of those five rows. CAGR uses the 5-year horizon and drops to 3-year only when both names report it. Research only — not a buy or sell.
What is the Anomaly Score on this ADXN page?
Anomaly Score is how unusual a filing pattern is versus this company’s own history and its industry — not the same as Misprise Score. A high anomaly with a weak Misprise Score is often a noisy name. Open the anomaly detector to see the flag. Research only — not financial advice.
What does the green grant dot mean on ADXN stock?
A green circle next to the title means this ticker appears in the Misprise grants calendar with a recent federal award (USASpending / SAM). Tap the dot for date, agency, and amount when available. It is a research flag only — not a buy or sell signal.
Is ADXN stock a buy?
No recommendation either way. This ADXN stock page organizes statements, ratios, and peers so you can do your own work. It is educational only — not advice to buy or sell Addex Therapeutics Ltd.